NCT01096862 is a Phase 2 clinical trial of peficitinib in Psoriasis, sponsored by Astellas Pharma Inc.

Who is sponsoring NCT01096862?

NCT01096862 is sponsored by Astellas Pharma Inc.

What drugs are being tested in NCT01096862?

Interventions in NCT01096862: peficitinib, Placebo.

Is NCT01096862 still recruiting?

NCT01096862 is currently completed. Last updated 21 October 2024.

Last reviewed 2024-10-21 · How we verify

NCT01096862

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis

Completed Phase 2 Last updated 21 October 2024

What this trial tests

Phase 2 trial testing peficitinib in Psoriasis in 124 participants. Completed in 27 July 2011.

Timeline

23 March 2010

Primary endpoint
27 July 2011

27 July 2011

Quick facts

Lead sponsor	Astellas Pharma Inc
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	124
Start date	23 March 2010
Primary completion	27 July 2011
Estimated completion	27 July 2011
Sites	11 locations across United States

Drugs / interventions tested

peficitinib — full drug profile →
Placebo

Conditions studied

Psoriasis — all drugs for Psoriasis →

Sponsor

Astellas Pharma Inc — full company profile →

Who can join

18 and older, any sex, with Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to explore the efficacy and safety of multiple, escalating doses of ASP015K when compared to placebo in subjects with moderate to severe plaque psoriasis.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach.
Tanaka Y, Luo Y, O'Shea JJ, Nakayamada S. · · 2022 · cited 329× · PMID 34987201 · DOI 10.1038/s41584-021-00726-8
Emerging Topical and Systemic JAK Inhibitors in Dermatology.
Solimani F, Meier K, Ghoreschi K. · · 2019 · cited 199× · PMID 31849996 · DOI 10.3389/fimmu.2019.02847
Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
Howell MD, Kuo FI, Smith PA. · · 2019 · cited 180× · PMID 31649667 · DOI 10.3389/fimmu.2019.02342
Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis.
Mease PJ, Armstrong AW. · · 2014 · cited 167× · PMID 24566842 · DOI 10.1007/s40265-014-0191-y
Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases.
T Virtanen A, Haikarainen T, Raivola J, Silvennoinen O. · · 2019 · cited 164× · PMID 30701418 · DOI 10.1007/s40259-019-00333-w
JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis.
Hsu L, Armstrong AW. · · 2014 · cited 88× · PMID 24883332 · DOI 10.1155/2014/283617
Systemic Treatment of Psoriasis with JAK Inhibitors: A Review.
Kvist-Hansen A, Hansen PR, Skov L. · · 2020 · cited 84× · PMID 31893355 · DOI 10.1007/s13555-019-00347-w
The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia.
Schroeder MA, Choi J, Staser K, DiPersio JF. · · 2018 · cited 82× · PMID 29289756 · DOI 10.1016/j.bbmt.2017.12.797

Verify or expand the search:

Other trials of peficitinib

Trials testing the same drug.

NCT04143477 — A Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese Subjects · Phase 1 · completed
NCT02760342 — A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Metformin · Phase 1 · completed
NCT02531191 — Bioequivalence Evaluation of a New and Current Tablet of ASP015K · Phase 1 · completed
NCT01711814 — A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rh · Phase 2 · completed
NCT01554696 — A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had · Phase 2 · completed

Other recruiting trials for Psoriasis

Currently open trials in the same condition.

NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria · NA · recruiting
NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis · recruiting
NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO) · recruiting
NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting
NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting

Other Astellas Pharma Inc trials

Trials by the same sponsor.

NCT07318714 — A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Stroke · Phase 1, PHASE2 · recruiting
NCT07094204 — A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors · Phase 1 · recruiting
NCT06970665 — A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Ma · Phase 4 · recruiting
NCT06364696 — A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors · Phase 1 · active not recruiting
NCT06206421 — A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01096862 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Astellas Pharma Inc
Last refreshed: 21 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01096862.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing